United States-based chemotherapy regimen for Ewing sarcoma is more effective and safer than the standard European regimen
1. The United States regimen had greater event-free survival and less associated febrile...
Read MoreNov 11, 2022
1. The United States regimen had greater event-free survival and less associated febrile...
Read MoreOct 31, 2022
1. In this study, individuals were found to experience peace at the end of life through...
Read MoreOct 31, 2022
1. A retrospective analysis demonstrated that prostate-specific antigen (PSA) screening has...
Read MoreOct 25, 2022
1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5...
Read MoreOct 25, 2022
1. In the pembrolizumab arm, distant metastasis-free survival was significantly improved and the...
Read MoreOct 21, 2022
1. Polycystic ovarian syndrome (PCOS) diagnosis puts women at 1.9 times higher risk of pancreatic...
Read MoreOct 21, 2022
1. After adjusting for aerobic moderate to vigorous physical activity (MVPA), weightlifting was...
Read MoreOct 21, 2022
1. In this systematic review and meta-analysis that included 16,597 patients, fine needle biopsy...
Read MoreOct 15, 2022
1. Atezolizumab was associated with non-significantly increased disease-free survival compared to...
Read MoreOct 15, 2022
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab...
Read MoreOct 15, 2022
1. Though not statistically significant, there was a U-shaped found between vitamin C levels and...
Read MoreOct 11, 2022
1. Objective response rate was not significantly different in patients treated with stereotactic...
Read MoreOct 11, 2022
Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage...
Read MoreOct 11, 2022
1. Almost half of patients (47%) had either an objective response or had progression free survival...
Read MoreOct 11, 2022
1. Median progression free survival was longer in the fulvestrant and palbociclib group compared...
Read MoreSep 28, 2022
1. Selpercatinib was found to have similar effective objective response rates compared to past...
Read MoreSep 28, 2022
1. Objective response rate was 43.9%. Patients treated with selpercatinib also experienced...
Read MoreSep 28, 2022
1. Patients in the active surveillance group who had forgone surgery had no difference in survival...
Read MoreSep 28, 2022
1. 25.8% of patients receiving chemotherapy for breast cancer experienced worsening frailty status. 2. Patients with both biomarkers (IL-6 and CRP) elevated before chemotherapy had a significantly higher risk of decline in...
Read MoreSep 22, 2022
1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in...
Read More